Skip to main
MDLN

Medline Inc (MDLN) Stock Forecast & Price Target

Medline Inc (MDLN) Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 35%
Buy 52%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Medline is well-positioned for long-term success with its strong brand reputation and established relationships with major US health systems. The company's diversified product portfolio, backed by extensive manufacturing and distribution capabilities, allows them to maintain competitive advantage and keep up with evolving industry trends. Furthermore, their partnership with Microsoft and investment in digital infrastructure showcases their commitment to innovation and adaptability in the rapidly changing healthcare landscape. The company's strong balance sheet and strategic initiatives make it a reliable and promising investment opportunity.

Bears say

Medline is a well-established distribution giant with a dominant market presence and strong customer relationships. However, the company's focus on automation and acquisition-driven growth comes at a high cost, making it vulnerable to technological changes and supply chain disruptions. Additionally, its heavy reliance on a few large customers poses a significant risk of revenue loss in the event of contract expiration or termination.

Medline Inc (MDLN) has been analyzed by 23 analysts, with a consensus rating of Buy. 35% of analysts recommend a Strong Buy, 52% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medline Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medline Inc (MDLN) Forecast

Analysts have given Medline Inc (MDLN) a Buy based on their latest research and market trends.

According to 23 analysts, Medline Inc (MDLN) has a Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $50.48, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $50.48, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medline Inc (MDLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.